Wells Fargo & Company Hoth Therapeutics, Inc. Transaction History

Wells Fargo & Company

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.36 - $9.25 $5 - $148	16 Added 8.08%	214 $0
Q2 2022 Aug 12, 2022	BUY	$0.38 - $1.05 $23 - $65	62 Added 45.59%	198 $0
Q1 2022 May 16, 2022	BUY	$0.52 - $1.3 $0 - $1	1 Added 0.74%	136 $0
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.62 $27 - $38	24 Added 21.62%	135 $0
Q2 2021 Aug 16, 2021	SELL	$1.31 - $2.14 $26,112 - $42,656	-19,933 Reduced 99.45%	111 $0
Q1 2021 May 13, 2021	BUY	$1.85 - $3.04 $37,005 - $60,809	20,003 Added 48787.8%	20,044 $39,000
Q3 2020 Nov 05, 2020	BUY	$1.86 - $3.15 $26 - $44	14 Added 51.85%	41 $0
Q1 2020 May 14, 2020	BUY	$2.62 - $6.59 $70 - $177	27 New	27 $0

Ticker HOTH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,288,470
Market Cap $1.04M
Description
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.